Document is current

Documents that mention this clinical trial

Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313

Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624

Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017

Notable surgical trials in gynecologic oncology: a 10-year overview
https://doi.org/10.1136/ijgc-2024-005471

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640

Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101

Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610

REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295

Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049

CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320

Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249

New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005

Documents that mention this clinical trial

Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313

Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624

Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017

Notable surgical trials in gynecologic oncology: a 10-year overview
https://doi.org/10.1136/ijgc-2024-005471

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640

Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101

Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610

REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295

Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049

CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320

Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249

New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005

Documents that mention this clinical trial

Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313

Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624

Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017

Notable surgical trials in gynecologic oncology: a 10-year overview
https://doi.org/10.1136/ijgc-2024-005471

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640

Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101

Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610

REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295

Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049

CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320

Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249

New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005

Documents that mention this clinical trial

Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640

2022-RA-798-ESGO Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)
https://doi.org/10.1136/ijgc-2022-esgo.562

REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295

Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)
https://doi.org/10.1136/ijgc-2019-000682